Castle Biosciences, a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the appointment of G. Bradley Cole to its Board of Directors.
Read More
Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma.
Read More
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.
Read More
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data from a new test discovered by the Company to assess the risk of cancer recurrence in patients diagnosed with soft tissue sarcomas (STS). Results were presented in a poster session at the Connective Tissue Oncology Society Annual Meeting, November 4-7, 2015 in Salt Lake City.
Read More →
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Federico A. Monzon, M.D. FCAP, to the newly created role of Chief Medical Officer. The Company also announced the appointment of Greg Schafer to Executive Director of Managed Care.
Read More →
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the Company has secured payer contracts with national provider networks MultiPlan, Inc., FedMed, Inc. and Preferred Medical Claim Solutions, LLC to provide coverage of its DecisionDx™ assays. These networks together provide access to more than 120 million covered lives.
Read More →
Gene expression profiling with a commercially available test (DecisionDx-Melanoma, Castle Biosciences) provides useful prognostic information for patients with high-risk cutaneous melanoma who undergo sentinel lymph node (SLN) biopsy, and particularly for those found to be node-negative, according to a study presented at the annual meeting of the American Society for Clinical Oncology.
Read More →
Castle Biosciences, Inc., a cancer-focused molecular diagnostics company, today announced the completion of an $11.8 million financing. The round was led by new investor HealthQuest Capital, with participation by Castle Biosciences’ current investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences’ Board of Directors.
Read More →